193 related articles for article (PubMed ID: 34130366)
1. A Network Meta-Analysis Comparing Osteoporotic Fracture among Different Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation.
Khanra D; Mukherjee A; Deshpande S; Khan H; Kathuria S; Kella D; Padmanabhan D
J Bone Metab; 2021 May; 28(2):139-150. PubMed ID: 34130366
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation.
Kuo LT; Lin SJ; Wu VC; Chang JJ; Chu PH; Lin YS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211011374. PubMed ID: 33995605
[TBL] [Abstract][Full Text] [Related]
3. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
[TBL] [Abstract][Full Text] [Related]
4. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
6. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
9. Comparative Risks of Fracture Among Direct Oral Anticoagulants and Warfarin: A Systematic Review and Network Meta-Analysis.
Tsai SHL; Hu CW; Shao SC; Tischler EH; Obisesan OH; Vervoort D; Chen WC; Hu JR; Kuo LT
Front Cardiovasc Med; 2022; 9():896952. PubMed ID: 35677694
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
11. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
13. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
14. Association of Direct Oral Anticoagulants vs. Vitamin K Antagonists With Fractures in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis.
Wu X; Hu L; Liu J; Gu Q
Front Cardiovasc Med; 2021; 8():713187. PubMed ID: 34368263
[No Abstract] [Full Text] [Related]
15. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Tornyos A; Kehl D; D'Ascenzo F; Komócsi A
Prog Cardiovasc Dis; 2016; 58(5):483-94. PubMed ID: 26674596
[TBL] [Abstract][Full Text] [Related]
16. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.
Binding C; Bjerring Olesen J; Abrahamsen B; Staerk L; Gislason G; Nissen Bonde A
J Am Coll Cardiol; 2019 Oct; 74(17):2150-2158. PubMed ID: 31648707
[TBL] [Abstract][Full Text] [Related]
17. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
[TBL] [Abstract][Full Text] [Related]
18. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
19. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
[TBL] [Abstract][Full Text] [Related]
20. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
